In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

A 34-year-old man was admitted to the hospital because of left ear pain with hearing loss and facial droop on the left side. Computed tomography showed a nasopharyngeal mass. A diagnosis was made.

The case description for a Case Records of the Massachusetts General Hospital appears below. A 61-year-old man presented with hypoxemic respiratory failure and shock 10 weeks after kidney ...

The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

The evolution of biomedical science can be appreciated through studies of hemoglobin, the oxygen-carrying protein in red cells. Before molecular cloning, the geneticist Arno Motulsky noted ...

Among 485 patients who were MRD-negative at 10 −5 sensitivity after induction, a premaintenance MRD-negative status at 10 −6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa ...

In a double-blind, randomized, placebo-controlled trial in Zimbabwe, we assigned pregnant women to receive trimethoprim–sulfamethoxazole, at a dose of 960 mg daily, or placebo from at least 14 ...

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain high.